Sangamo Therapeutics Inc (NASDAQ:SGMO) – Equities research analysts at Wedbush issued their Q1 2018 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday, March 13th, according to Zacks Investment Research. Wedbush analyst L. Moussatos forecasts that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter. Wedbush currently has a “Hold” rating and a $8.00 target price on the stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q2 2018 earnings at $0.03 EPS, Q3 2018 earnings at $0.03 EPS, Q4 2018 earnings at $0.03 EPS, FY2018 earnings at $0.00 EPS, FY2019 earnings at $0.04 EPS, FY2020 earnings at ($0.91) EPS, FY2021 earnings at ($1.26) EPS and FY2022 earnings at ($1.30) EPS.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The business’s revenue for the quarter was up 46.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.14) EPS.
Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. Barclays reaffirmed a “buy” rating and issued a $30.00 target price on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Piper Jaffray set a $25.00 target price on shares of Sangamo Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.83.
Shares of SGMO traded down $0.55 during trading hours on Friday, hitting $16.95. The stock had a trading volume of 2,534,756 shares, compared to its average volume of 2,049,350. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.54 and a current ratio of 5.54. Sangamo Therapeutics has a 52 week low of $4.05 and a 52 week high of $27.50. The firm has a market cap of $1,463.45, a price-to-earnings ratio of -24.21 and a beta of 2.80.
A number of hedge funds and other institutional investors have recently modified their holdings of SGMO. Quantbot Technologies LP acquired a new position in Sangamo Therapeutics during the 3rd quarter worth about $118,000. Fred Alger Management Inc. acquired a new position in Sangamo Therapeutics during the 4th quarter worth about $148,000. Amalgamated Bank acquired a new position in Sangamo Therapeutics during the 3rd quarter worth about $158,000. Xact Kapitalforvaltning AB acquired a new position in Sangamo Therapeutics during the 4th quarter worth about $175,000. Finally, Great West Life Assurance Co. Can lifted its position in Sangamo Therapeutics by 150.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 7,667 shares in the last quarter. Institutional investors and hedge funds own 64.68% of the company’s stock.
In related news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $20.59, for a total transaction of $308,850.00. Following the transaction, the vice president now owns 29,625 shares in the company, valued at approximately $609,978.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 89,896 shares of company stock worth $1,950,712. 5.50% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/sangamo-therapeutics-inc-forecasted-to-post-q1-2018-earnings-of-0-08-per-share-sgmo.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.